S3607

S.3607 (Access to Genetic Counselor Services Act of 2026) was introduced on January 8, 2026 by Sen. Barrasso (R-WY) with three cosponsors: Sen. Welch (D-VT), Sen. Capito (R-WV), and Sen. Rosen (D-NV). The bill has been referred to the Senate Committee on Finance. A companion bill, HR6280, exists in the House, referred to the Energy and Commerce and Ways and Means Committees. This bicameral, bipartisan sponsorship signals moderate legislative momentum, but the bill remains in early stages — no hearings or markups have occurred. The bill does NOT appropriate new funding. It amends the Social Security Act to add genetic counselors as a covered provider type under Medicare Part B, effective January 1, 2027. This is an authorization of coverage, not a spending authorization. The actual spending impact will depend on utilization rates by the ~63 million Medicare beneficiaries. Payment is set at 80% of the lesser of the actual charge or a fee schedule to be determined by CMS. The mechanism is regulatory — it creates a new billing category, which expands the addressable market for downstream diagnostic services. The structural winners are diagnostic lab companies Labcorp and Quest Diagnostics. Genetic counseling is a gateway service for genetic testing — patients see a counselor, discuss risk factors, and are typically referred for a laboratory test. Currently, Medicare's coverage gap for non-physician genetic counselors creates a bottleneck; this bill removes it. Both LH and DGX have large genetic testing menus (hereditary cancer panels, prenatal screening, pharmacogenomics) that directly benefit from increased counseling-driven orders. AMN Healthcare benefits as the primary pure-play staffing provider for allied health; genetic counselors are a small but high-demand specialty, and Medicare coverage will accelerate hiring. Examining the provided market data: Over the trailing 30 days (to April 30, 2026), $LH is down -1.49%, $DGX is nearly flat at -0.11%, while $AMN is up +12.43%. Over 7 days, LH and DGX are slightly negative (-0.37% and -0.25% respectively), while AMN gained +1.33%. AMN's strong 30-day performance (+12.43%) may reflect broader healthcare staffing recovery and the bill's introduction in January providing a sentiment lift. The lab stocks are near the middle of their 52-week ranges (LH $235.81-$293.72, current $262.83; DGX $164.65-$213.50, current $195.77), suggesting the bill's early-stage status has not yet been priced in significantly. The timeline: The bill must pass the Senate Finance Committee, the full Senate, the House, and be signed by the President. With the effective date of January 1, 2027, there is a ~8-month runway from today. Given the 119th Congress runs through January 2027, passage by mid-2026 would allow CMS time to implement fee schedules. A realistic probability of passage is moderate — the bipartisan sponsorship and companion bill are positive signals, but this is not a high-priority leadership bill. If enacted, the impact on lab volumes would be gradual, likely materializing in late 2027 and 2028 as providers build capacity.